As of 10:57:30 AM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
6,370.7870
13,477.5000
17,897.9650
15,641.0030
5,648.1120
Operating Income
-6,370.7870
-13,477.5000
-17,897.9650
-15,641.0030
-5,648.1120
Net Non Operating Interest Income Expense
-51.4740
-44.8280
-26.6670
-186.2080
-1,086.9740
Other Income Expense
3,296.0840
-8,762.1980
-21,744.3760
-4,520.6410
-4,169.3990
Pretax Income
-3,126.1770
-22,284.5260
-39,669.0080
-20,347.8520
-10,904.4850
Tax Provision
-4.3890
-2,349.4140
-942.7490
-23.2040
-20.4270
Net Income Common Stockholders
-3,121.7880
-19,935.1120
-38,726.2590
-20,324.6480
-12,006.7600
Diluted NI Available to Com Stockholders
-3,121.7880
-19,935.1120
-38,726.2590
-20,324.6480
-12,006.7600
Total Operating Income as Reported
-6,370.7870
-13,477.5000
-17,897.9650
-15,641.0030
-5,648.1120
Total Expenses
6,370.7870
13,477.5000
17,897.9650
15,641.0030
5,648.1120
Net Income from Continuing & Discontinued Operation
-3,121.7880
-19,935.1120
-38,726.2590
-20,324.6480
-10,884.0580
Normalized Income
-3,127.3851
-11,900.1288
-17,503.7480
-15,049.2787
-6,458.7883
Interest Income
--
--
1.5080
--
--
Interest Expense
51.4740
44.8280
28.1750
186.2080
1,086.9740
Net Interest Income
-51.4740
-44.8280
-26.6670
-186.2080
-1,086.9740
EBIT
-3,074.7030
-22,239.6980
-39,640.8330
-20,161.6440
-9,817.5110
EBITDA
-2,990.6350
-22,134.0230
-39,531.8290
-20,051.6970
-9,692.1780
Reconciled Depreciation
84.0680
105.6750
109.0040
109.9470
125.3330
Net Income from Continuing Operation Net Minority Interest
-3,121.7880
-19,935.1120
-38,726.2590
-20,324.6480
-10,884.0580
Total Unusual Items Excluding Goodwill
5.6050
-8,987.6770
-21,744.3760
-5,291.2430
-4,434.1380
Total Unusual Items
5.6050
-8,987.6770
-21,744.3760
-5,291.2430
-4,434.1380
Normalized EBITDA
-2,996.2400
-13,146.3460
-17,787.4530
-14,760.4540
-5,258.0400
Tax Rate for Calcs
0.0000
0.0001
0.0000
0.0000
0.0000
Tax Effect of Unusual Items
0.0079
-952.6938
-521.8650
-15.8737
-8.8683
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LIXTW Lixte Biotechnology Holdings, Inc.
0.0209
0.00%
APLMW Apollomics, Inc.
0.0096
-3.03%
PTIXW Protagenic Therapeutics, Inc.
0.0140
0.00%
GOVXW GeoVax Labs, Inc.
0.1122
-0.09%
TCBPW TC Biopharm (Holdings) Plc
0.0147
+61.54%
CDTTW Conduit Pharmaceuticals Inc.
0.0153
+39.09%
LEXXW Lexaria Bioscience Corp.
0.8000
+10.28%
PMVP PMV Pharmaceuticals, Inc.
1.5800
0.00%
XBIO Xenetic Biosciences, Inc.
4.0101
-2.19%
RVPHW Reviva Pharmaceuticals Holdings, Inc.
0.3300
+6.45%